CME in Minutes: Education in Oncology & Hematology

Please visit answersincme.com/860/97150451-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss treatment strategies for resectable and unresectable disease while highlighting ways to optimize long-term outcomes. Upon completion of this activity, participants should be better able to: Review the implications of the latest evidence evaluating immunotherapy (IO)-based regimens in resectable and unresectable early-stage non-small cell lung cancer (NSCLC); and Integrate patient-centered care into the management of early-stage NSCLC.

Please visit answersincme.com/UNP860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in hepatology discusses the latest evidence and guideline recommendations for the first-line treatment of unresectable hepatocellular carcinoma. Upon completion of this activity, participants should be better able to: Review the guideline-recommended preferred treatment options for management of unresectable HCC; and Recognize key clinical factors that should be considered when optimizing management for patients with unresectable HCC.

Please visit answersincme.com/860/99120473-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in oncology discuss the latest advances in HER2- and TROP2-directed ADCs for the management of advanced NSCLC, and how these approved and emerging ADCs may impact patients’ treatment algorithms. Upon completion of this activity, participants should be better able to: Identify the rationale for targeting HER2 and TROP2 in the treatment of non-small cell lung cancer (NSCLC; Discuss the clinical impact of approved and emerging HER2- and TROP2-directed antibody-drug conjugates (ADCs) in NSCLC; and Formulate evidence-based strategies for the individualized management of patients with NSCLC using HER2- and TROP2-directed ADCs.

Please visit answersincme.com/860/IME-2025-21131-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in hematology/oncology discuss use of anti-CD38 monoclonal antibody–based quadruplet regimens in the treatment of patients with newly diagnosed multiple myeloma (NDMM). Upon completion of this activity, participants should be better able to: Identify the rationale for anti-CD38 monoclonal antibody–based quadruplet regimens in the treatment of patients with newly diagnosed multiple myeloma (NDMM); Evaluate the clinical implications of evidence on anti-CD38 monoclonal antibody–containing quadruplet therapies in patients with NDMM; and Review strategies to optimize anti-CD38 monoclonal antibody–containing quadruplet therapies, including in the community setting.

Please visit answersincme.com/860/MED-ONC-03650-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in the management of squamous non–small-cell lung cancer (NSCLC) discuss guideline-based treatment selection, clinical factors guiding the personalization of immunotherapy plans, and long-term strategies to optimize outcomes in squamous disease. Upon completion of this activity, participants should be better able to: Assess guideline-based recommendations and biomarker profiles to inform first-line immunotherapy-based treatment selection for squamous NSCLC; Identify clinical factors that may be used to tailor first-line immunotherapy-based approaches across a range of PD-L1 expression levels and patient subtypes; and Recommend long-term, real-world clinical approaches to optimize the risk/benefit profiles of immunotherapy-based treatments in patients with squamous NSCLC.